Podcasts about Cis

revengeofthecis.locals.com    

This week, a man who never quite made the impact he wanted to, in the NFL, despite his Notre Dame pedigree. Whenever his talent would get him to a good spot, he'd screw it up, with his actions. He was out of the NFL, by age 25, and ready to start being an even worse person. The prison sentence he's currently serving, is for a crime that was so horrific, the judge wished he could sentence him to even more time. A true monster!   Start football late, but have your natural abilty take you to the highest levels, screw up every oppurtunity that you have, and get convicted of a crime that would make any half decent person want to strangle you, with their bare hands with Cierre Wood!!   Check us out, every Tuesday! We will continue to bring you the biggest idiots in sports history!!   Hosted by James Pietragallo & Jimmie Whisman   Donate at... patreon.com/crimeinsports or with paypal.com using our email: crimeinsports@gmail.com Get all the CIS, STM & YSO merch at crimeinsports.threadless.com   Go to shutupandgivememurder.com for all things CIS, STM & YSO!!   Contact us on... instagram.com/smalltownmurder facebook.com/crimeinsports crimeinsports@gmail.com

Episode 1547: Free Speech 101

Trans kids exist, and they need your support. No, they're not getting surgeries... but cis kids and intersex kids sure are! Hopefully that bothers you, but it sure doesn't bother the people trying to take away the literally lifesaving care that trans kids need. Get a whole mountain of facts within, so you finally understand what's really going on (and why the entire legitimate professional healthcare industry is opposed to outlawing care for trans kids). Karla, the cis mom of a trans kid, joins us to discuss how you should give your kids agency! TEXT VERSION https://www.tillystranstuesdays.com/2024/08/09/trans-kids-and-the-intake-exam/ FURTHER READING (topics discussed with essays available at http://TillysTransTuesdays.com) Trans Parents (Mother's Day), Gender Dysphoria, The Signs Were Always There (that we're trans), Searching for Meaning (when you're trans and don't know it), Gendered Childhoods, Trans Trauma 2: Societal Gaslighting, The Past and Why it Haunts Us, The Past 2: The New Past (KJ and Paper Girls), The Past 3: Trans Grief 1, The Past 4: Trans Grief 2, The Past 5: Recovering Trans Childhoods, Trans Sports 1: Origins and "Advantages", Trans Sports 2: Science and Bigotry, The 2022 US Trans Survey Results part 4, Cis People Get Gender Affirming Healthcare Too, Hormone Replacement Therapy REFERENCE MATERIAL Trans youth as consistent in their identity as cis youth, study shows - https://www.thepinknews.com/2025/08/19/trans-youth-regret-incredibly-low/ Puberty blockers: Under-16s 'unlikely to be able to give informed consent' - https://www.bbc.com/news/uk-england-cambridgeshire-55144148 2025 anti-trans bills tracker - https://translegislation.com/ Anti-Trans National Legal Risk Assessment Map - https://www.erininthemorning.com/p/anti-trans-national-legal-risk-assessment Children's Hospital LA closes its gender-affirming care center - https://laist.com/news/health/in-a-landmark-move-childrens-hospital-la-closes-its-gender-affirming-care-center-today Governor Newsom's Comments on Transgender Student Athletes - https://www.eqca.org/newsom-trans-remarks/ Suicidality Among Transgender Youth - https://pubmed.ncbi.nlm.nih.gov/32345113/ Doctors Agree: Gender-Affirming Care is Life-Saving Care - https://www.aclu.org/news/lgbtq-rights/doctors-agree-gender-affirming-care-is-life-saving-care Legislation to Criminalize Gender-Affirming Medical Care for Transgender Youth - https://jamanetwork.com/journals/jama/article-abstract/2780517 Gender-Critical Policy Causes Brain Damage in Trans Youth - https://www.transadvocate.com/gender-critical-policy-causes-brain-damage-in-trans-youth-affirmative-care-vs-preventive-interventions_n_95857.htm Prevalence of Gender-Affirming Surgical Procedures Among Minors and Adults in the US - https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2820437 Medically Unnecessary Surgeries on Intersex Children in the US - https://www.hrw.org/report/2017/07/25/i-want-be-nature-made-me/medically-unnecessary-surgeries-intersex-children-us# Tall girls, short boys: Using hormone therapy to shape children's height to social norms - https://news.umich.edu/tall-girls-short-boys-using-hormone-therapy-to-shape-childrens-height-to-social-norms/ Cis boys get gender-affirming surgeries more often than trans minors - https://www.lgbtqnation.com/2024/07/cis-boys-get-gender-affirming-surgeries-more-often-than-transgender-minors/ Fewer than 1 in 1,000 US adolescents receive gender-affirming medications - https://apnews.com/article/transgender-hormones-puberty-blockers-youth-562cba3c3ae43e88d5144f7adb4efd7c No One Had a Problem With Puberty Blockers When Only Cis Kids Took Them - https://www.vice.com/en/article/no-one-had-a-problem-with-puberty-blockers-when-only-cis-kids-took-them/ Gender-Affirming Care for Trans Youth Is Neither New nor Experimental - https://juliaserano.medium.com/gender-affirming-care-for-trans-youth-is-neither-new-nor-experimental-a-timeline-and-compilation-b4bb8375d797 Emotional Health of Transgender Youth 24 Months After Initiating Gender-Affirming Hormone Therapy - https://www.sciencedirect.com/science/article/abs/pii/S1054139X24005664?dgcid=author Special thanks to Daisy and Jane for the use of "Sorry Not Sorry" as our show's theme music. Please stop by and show your support at daisyandjane.bandcamp.com and soundcloud.com/daisyandjane --Please leave us a rating on Apple Podcasts/iTunes!-- Website: pendantaudio.com Bluesky: @pendantaudio.bsky.social‬

En COPE, se analiza la profunda crisis diplomática entre España e Israel. Pedro Sánchez critica la actuación israelí en Gaza, lo que lleva a la convocatoria de la embajadora israelí en Madrid y al anuncio de posibles cancelaciones de contratos de defensa. Se informa sobre la sostenibilidad del sistema de pensiones, con el gobierno asegurando su viabilidad y los economistas advirtiendo sobre déficits y problemas demográficos, especialmente en comunidades como Andalucía y el País Vasco. También se aborda el impacto de la Inteligencia Artificial (ChatGPT) en la educación, planteando interrogantes sobre la posible destrucción de hábitos intelectuales y la existencia de un sesgo de clase en su uso. Se menciona la situación de las huelgas de seguridad en el aeropuerto de Barajas y las críticas a las encuestas del CIS.

Episode 1546: Cashapp Paypal

https://morelikeradio.org/locals-ep-229-a-turning-point/feed/ 0

Episode 1545: R.I.P. Moderate Right    

Se debate la intención de voto según el CIS, con el PSOE liderando y el PP descendiendo. También se habla del asesinato de Charlie Kirk en EE. UU., la recompensa por información y detalles del sospechoso. La Policía Nacional de Santiago entrega un cheque de 31.000€ a la asociación de Esclerosis Múltiple, que ayudará a contratar un profesional sanitario. Elsa, con 19 años y ELA infantil, comienza sus estudios de psicología para ser criminóloga. Se anuncia que Dani Fernández y Yarea crearán el himno de CADENA 100 por Ellas 2025, presentándolo el 18 de octubre en el Movistar Arena. Se discute la importancia del humor y las anécdotas que los camareros presencian. Lady Gaga es elogiada por su versatilidad. Se mencionan las comidas favoritas de Dani Martín (cocido madrileño), Pablo Alborán (espeto) y Manuel Carrasco (atún rojo).

Se informa sobre el tiempo: un viernes muy tranquilo, con algo de lluvia en el norte de Cataluña, Barcelona, Castellón y Teruel, y temperaturas que alcanzan los 35 grados en el Guadalquivir. Una encuesta del CIS indica que el PSOE ganaría las elecciones con un 32%. Se debate el asesinato de la activista Charlie Kirk en EE.UU., ofreciéndose recompensas de hasta 100.000 dólares por información. El Parque de María Luisa en Sevilla cierra por posible gripe aviar. La Policía Nacional de Santiago entrega 31.000 euros a la Asociación de Esclerosis Múltiple. Se anuncia que hoy a las 8:00 se desvelará quién creará el himno de CADENA 100 por Ellas, con concierto el 18 de octubre. Se escucha música de Alphaville, Leire Martínez, Coldplay, Fito & Fitipaldis y Ed Sheeran. Se informa que el IPC de agosto se mantuvo en el 2,7% y el BCE no ha tocado los tipos de interés. Damiano David presenta 'Next Summer'. Los niños comparten lo que no les gusta de su familia.

Carlos Alsina ha repasado su entrevista con la ministra de Trabajo, Yolanda Díaz, los últimos pronósticos de intención de voto del CIS y la bajada de afluencia en las manifestaciones de la Diada.

El programa en COPE destaca la actualidad informativa y deportiva. Se analiza la situación del toreo, con mención a figuras como Morante y sus problemas de salud. En política, se critica la encuesta del CIS de Tezanos y la gestión del gobierno, especialmente la propuesta de Yolanda Díaz sobre la reducción de la jornada laboral, vista como una medida demagógica y gaseosa. Se observa una disminución en la participación de la Diada catalana, mientras el independentismo gana peso institucional. La visita del Secretario de Comercio de EE. UU. a España para reunirse con el gobierno y el viceprimer ministro chino es un punto clave en la agenda internacional. El Real Madrid jugará la final de la Champions en 2027 en el Metropolitano. Además, se aborda el asesinato político en EE. UU., comparándolo con el terrorismo en España y la justificación de la violencia. Los tertulianos debaten sobre la "superioridad moral" de cierta izquierda y la perversión de la democracia, criticando a los ...

El audio aborda la compleja cuesta de septiembre para las familias, destacando los elevados gastos extraescolares y la búsqueda de conciliación. Expertos recomiendan un máximo de dos extraescolares. Ryanair amenaza con recortes si AENA no baja las tasas aeroportuarias, pero el gobierno rechaza lo que considera un chantaje. En política, el Partido Popular no cree el último sondeo del CIS y asegura tener datos internos que le permitirían gobernar en solitario. Un tema recurrente es el fenómeno de mujeres maduras que eligen vivir sin pareja, prefiriendo su paz mental a relaciones que no prometen futuro. Expertos y figuras públicas como Antonia San Juan analizan que no rechazan el amor, sino procesos agotadores. La soledad elegida se valora como un espacio de bienestar personal. En el ámbito de la nutrición, se debate el uso de ChatGPT para crear dietas, mostrando un menú de ejemplo. Profesionales como Sandra Moñino advierten sobre la falta de personalización, la necesidad de una ...

Tiempo de análisis con los periodistas Juan Gavasa, Roberto Pérez y Ángel González Abad: Debate sobre las malas cifras de accidentes laborales en Aragón con 27 muertos en lo que va de año: hay reunión extraordinaria del Consejo de Salud Laboral. En las Cortes de Aragón la consejera Susín ha pedido respuestas para poder planificar la acogida de menores migrantes mientras que el consejero Bermúdez de Castro ha explicado la respuesta de Emergencias a las tormentas de este verano: Reabre la carretera A 222 en Belchite tras las inundaciones de junio. Analisis del resultado del CIS y de la decisión de Ursula Von Der Leyen, avalada por el Parlamento Europeo, de suspender el pacto comercial con Israel. Cerramos con las quejas del colectivo Stop Ruido por el incivismo en el casco histórico de Zaragoza y con los primeros mundiales de atletismo que piden el test de feminidad y que empiezan este fin de semana en Pekín.

Luis Herrero analiza junto a Esmeralda Ruiz, Laura Fábregas y Maite Loureiro la última encuesta del CIS.

Rafa Latorre reflexiona en 'La Brújula' sobre los resultados del CIS sobre los posibles escenarios electorales y sobre la coincidencia entre el aniversario del 11-S y el asesinato ayer del activista conservador Charlie Kirk

El CIS de Tezanos es una pieza fundamental en la estrategia propagandística del sanchismo. Es verdad que la manipulación es tan zafia como disparatada, pero cumple la misión que tiene encomendada su máximo responsable. Los datos electorales que ofreció este jueves reflejan el nivel de degradación en que se encuentra este organismo público. La mejor prueba de que sus resultados no son fiables es que ni siquiera los medios de comunicación afectos al régimen sanchista se los toman en serio. 

https://revengeofthecis.locals.com/    

On last week's episode of Unsupervised Learning, Razib spoke with Alex Nowrestah, a vice president at the Cato Institute and a strong advocate for expanding legal immigration. This week, he turned to the other side of the debate with Jason Richwhine, a resident scholar at the Center for Immigration Studies and a vocal supporter of sharply reducing immigration. Richwine earned undergraduate degrees in mathematics and political science from American University, and later a Ph.D. in public policy from Harvard. Before joining CIS, he served as deputy director of the National Institute of Standards and Technology and worked as a senior policy analyst at the Heritage Foundation. The conversation begins with an overview of the dramatic swings in U.S. immigration policy under Biden and Trump. Both note the surge of the foreign-born population in the early 2020s, with the unauthorized share now estimated at 15-16 million. Richwine faults Biden for lax border enforcement and the abuse of parole programs, and points to the comparative effectiveness of Trump's Remain in Mexico policy. He also presses the case for a moratorium, arguing that even legal immigration must be scaled back to sustainable levels. Razib and Richwine weigh the economic and cultural consequences of high-skilled immigration and close by considering whether meaningful reform is politically possible in the years ahead.

In episode 152 of Cybersecurity Where You Are, Sean Atkinson is joined by Cliff Moten, Manager, Cybersecurity Solutions Engineering at the Center for Internet Security® (CIS®); and Richard Vargas, Security Operations Center Manager at CIS. Together, they discuss how the 24x7x365 CIS Security Operations Center (SOC) and CIS Managed Detection and Response™ (CIS MDR™) work together to accelerate response time while enriching telemetry. Here are some highlights from our episode:01:40. Demystifying SOCs and MDR as cybersecurity concepts02:52. How the CIS SOC works to provide information, context, and next steps for an event05:04. Artificial intelligence and automation as ways to accelerate response time10:20. Real-world instances where a fast response time made a difference13:10. What it means to support underfunded organizations with the resources they need17:22. The role of contextual cyber threat intelligence in accelerating response times19:01. The value of security orchestration, automation, and response (SOAR) in helping defenders move quickly27:33. Lessons that organizations can use to cut down on their incident response timesResourcesThe CIS Security Operations Center (SOC): The Key to Growing Your SLTT's Cyber MaturityEpisode 148: How MDR Helps Shine a Light on Zero-Day AttacksEpisode 144: Carrying on the MS-ISAC's Character and CultureEpisode 137: National Cybersecurity Through SLTT ResilienceCombatting RansomwareEstablishing Essential Cyber HygieneCIS Community Defense Model 2.0If you have some feedback or an idea for an upcoming episode of Cybersecurity Where You Are, let us know by emailing podcast@cisecurity.org.

This week, a longtime UFC mainstay, and notoriously colorful character, who always seems to say the exact wrong thing. Mostly, at the exact wrong time. Training alongside his brother, from a young age, he knew his path to success would be through fighting. Sometimes, that fighting isn't in the ring. Sometimes, it's out in the street, or backstage at an event. It could happen anywhere. He didn't commit the most "crimes", but his general demeanor, and big mouth, makes him quite the story!   Start fighting, both in & out of the ring, at a young age, help the UFC become a major sports organization, and always say the wrong thing, but if talking doesn't work, always choke your problems away with Nate Diaz!!   Check us out, every Tuesday! We will continue to bring you the biggest idiots in sports history!!   Hosted by James Pietragallo & Jimmie Whisman   Donate at... patreon.com/crimeinsports or with paypal.com using our email: crimeinsports@gmail.com Get all the CIS, STM & YSO merch at crimeinsports.threadless.com   Go to shutupandgivememurder.com for all things CIS, STM & YSO!!   Contact us on... instagram.com/smalltownmurder facebook.com/crimeinsports crimeinsports@gmail.com

Episode 1544: Daisy Ooof

Episode 1543: 2 Fatigue 2 Relax

https://revengeofthecis.locals.com/ https://www.patreon.com/c/WereNotSorry

Episode 1542: The Magic Bullet

Dr. Sumanta (Monty) Pal and Dr. Petros Grivas discuss innovative new intravesical therapies and other recent advances in the treatment of non-muscle invasive bladder cancer. TRANSCRIPT Dr. Sumanta (Monty) Pal: Hello and welcome. I'm Dr. Monty Pal here at the ASCO Daily News Podcast. I'm a medical oncologist and professor and vice chair of academic affairs at the City of Hope Comprehensive Cancer Center in Los Angeles. And I'm really delighted to be your new host here. Today's episode is going to really sort of focus on an area near and dear to my heart, something I actually see in the clinics, and that's bladder cancer. We're specifically going to be discussing non-muscle invasive bladder cancer, which actually comprises about 75% of new cases. Now, in recent years, there's been a huge shift towards personalized bladder-preserving strategies, including innovative therapies and new agents that really are reducing reliance on more primitive techniques like radical cystectomy and radiation therapy. And I'm really excited about this new trend. And really at the forefront of this is one of my dear friends and colleagues, Dr. Petros Grivas. He's a professor in the Department of Medicine and Division of Hematology Oncology at the University of Washington. It's going to take a while to get through all these titles. He's taken on a bunch of new roles. He is medical director of the International Program, medical director of the Local and Regional Outreach Program, and also professor in the Clinical Research Division at the Fred Hutch Cancer Center. Petros, welcome to the program. Dr. Petros Grivas: Thank you so much, Monty. It's exciting for me to be here. Dr. Sumanta (Monty) Pal: Just FYI for our audience, our disclosures are available in the transcript of this episode.  We're going to get right into it, Petros. Non-muscle invasive bladder cancer, this is a really, really challenging space. We see a lot of recurrence and progression of the disease over time, about 50% to 70% of patients do have some recurrence after initial treatment, and about 30% are ultimately going to progress on to muscle-invasive or metastatic disease. Now, I will say that when you and I were in training, non-muscle invasive bladder cancer was something that was almost relegated to the domain of the urologist, right? They would use treatments such as BCG (Bacillus Calmette-Guérin) in a serial fashion. It was rare, I think, for you and I to really enter into this clinical space, but that's all changing, isn't it? I mean, can you maybe tell us about some of the new therapies, two or three that you're really excited about in this space? Dr. Petros Grivas: Monty, you're correct. Traditionally and conventionally, our dear friends and colleagues in urology have been managing patients with non-muscle invasive bladder cancer. The previous term was superficial bladder cancer. Now, it has changed, to your point, to non-muscle invasive bladder cancer. And this has to do with the staging of this entity. These tumors in superficial layers of bladder cancer, not invading the muscularis propria, the muscle layer, which makes the bladder contract for urine to be expelled. As you said, these patients have been treated traditionally with intravesical BCG, one of the oldest forms of immunotherapy that was developed back in the 1970s, and this is a big milestone of immunotherapy development. However, over the years, in the last 50 years, there were not many options for patients in whom the cancers had progression or recurrence, came back after this intravesical BCG. Many of those patients were undergoing, and many of them still may be undergoing, what we call radical cystectomy, meaning removal of the bladder and the lymph nodes around the bladder. The development of newer agents over the last several years has given the patients the option of having other intravesical therapies, intravesical meaning the delivery of drugs, medications inside the bladder, aiming to preserve the bladder, keep the bladder in place. And there are many examples of those agents. Just to give you some examples, intravesical chemotherapy, chemotherapy drugs that you and me may be giving intravenously, some of them can be given inside the bladder, intravesical installation. One example of that is a combination of gemcitabine and docetaxel. These drugs are given in sequence one after the other inside the bladder, and they have seen significant efficacy, good results, again, helping patients keeping the bladder when they can for patients with what we call BCG unresponsive non-muscle invasive bladder cancer. And again, there's criteria that the International Bladder Cancer Group and the FDA developed, how to define when BCG fails, when we have BCG unresponsive non-muscle invasive bladder cancer. Dr. Sumanta (Monty) Pal: And we're actually going to get into some of the FDA requirements and development pathways and so forth. What I'm really interested in hearing, and I'm sure our audience is too, are maybe some of the new intravesical treatments that are coming around. I do think it's exciting that the gemcitabine and docetaxel go into the bladder indeed, but what are some of the top new therapies? Pick two or three that you're excited about that people should be looking out for in this intravesical space. Dr. Petros Grivas: For sure, for sure. In terms of the new up-and-coming therapies, there are a couple that come to mind. One of them is called TAR-200, T-A-R 200. This agent is actually a very interesting system. It's an intravesical delivery of a chemotherapy called gemcitabine, the one that I just mentioned a few minutes ago, that is actually being delivered through what we call a pretzel, which is like a rounded [pretzel-shaped] structure working like an osmotic pump, and that is being delivered inside the bladder intravesically by urologists. And this drug is releasing, through the osmotic release mechanism, this chemotherapeutic drug, gemcitabine, inside the bladder. And this can be replaced once every 3 weeks in the beginning. And the data so far from early-phase trials are really, really promising, showing that this agent may be potentially regulatory approved down the road. So TAR-200 is something to keep in mind. And similarly, in the same context, there is a different drug that also uses the same mechanism, and this osmotic release, this pretzel, it's just encoded with a different agent. The different agent is an FGFR inhibitor, a target therapy called erdafitinib, a drug that you and me may give in patients with metastatic urothelial carcinoma if they have an FGFR3 mutation or fusion. And that drug is called TAR-210. Dr. Sumanta (Monty) Pal: And can I ask you, in that setting, do you have to have an FGFR3 mutation to receive it? Or what is the context there? Dr. Petros Grivas: So for TAR-210, TAR-2-1-0, usually there is a checking to see if there is an FGFR3 mutation or fusion. And the big question, Monty, is do we have adequate tissue, right? From a limited tissue on what we call the TURBT, right, that urologists do. And now there is a lot of development in technology, for example, urine circulating tumor DNA to try to detect these mutations in the urine to see whether the patient may be eligible for this TAR-210. Both of those agents are not FDA approved, but there are significant promising clinical trials. Dr. Sumanta (Monty) Pal: So now let's go to a rapid-fire round. Give us two more agents that you're excited about in this intravesical space. What do you think? Dr. Petros Grivas: There is another one called cretostimogene. It's a long name. Dr. Sumanta (Monty) Pal: They really make these names very easy for us, don't they? Dr. Petros Grivas: They are not Greek names, Monty, I can tell you, you know. Even my Greek language is having trouble pronouncing them. The cretostimogene, it's actually almost what we call a growth factor, a GM-CSF. The actual name of this agent is CG0070. This is a replicating mechanism where GM-CSF is replicating in cells. And this agent has shown significant results again, like the TAR-200, in BCG unresponsive non-muscle invasive bladder cancer. I would say very quickly, two agents that actually were recently approved and they're already available in clinical practice, is nadofaragene firadenovec, another long name. That's a non-replicating vector that has the gene of interferon alfa-2b that stimulates the immune system in the bladder. It's given once every 3 months. And the last one that was, as I mentioned, already FDA approved, it's an interleukin-15 superagonist. It's another long name, which is hard to pronounce, but I will give it a try. It's a drug that was recently actually approved also in the UK. The previous name was N-803. It's given together with BCG as a combination for BCG unresponsive non-muscle invasive bladder cancer. Dr. Sumanta (Monty) Pal: This is a huge dilemma, I think, right? Because if you're a practicing, I'm going to say urologist for the moment, I guess the challenge is how do you decide between an IL-15 superagonist? How do you decide between a pretzel-eluting agent? How do you decide between that and maybe something that's ostensibly, I'm going to guess, cheaper, like gemcitabine and docetaxel? What's sort of the current thinking amongst urologists? Dr. Petros Grivas: Multiple factors play into our account when the decision is being made. I discuss with urologists all the time. It's not an easy decision because we do not have head-to-head comparisons between those agents. As you mentioned, intravesical chemotherapy with gemcitabine and docetaxel has been used over the years and this is the lowest cost, I would say, the cheapest option with good efficacy results. Obviously, the nadofaragene firadenovec every 3 months and the interleukin-15 superagonist, N-803, plus BCG have also been approved. The question is availability of those agents, are they available? Are they reimbursed? Cost of those agents can come into play. Frequency of administration, you know, once every 3 months versus more frequent. And of course, the individual efficacy and toxicity data, preference of the patients; sometimes the provider, the urologist, may have something that they may be more familiar with. But we lack this head-to-head comparison. Of course, I want to make sure I mention that radical cystectomy may still be the option for appropriate patients. So that complicates also the decision making and has to be individualized, customized, and personalized, taking into account all those factors. And there is not one size fitting all. Dr. Sumanta (Monty) Pal: So I think we discussed five intravesical therapies. As you point out, and you know, I'm going to get some calls about this: I think I referred to radical cystectomy as being a more primitive procedure. Not true at all. I think it's something that still is, you know, a mainstay of management in this disease space. But I guess it gets even more complicated, am I right, Petros? Because now we have systemic therapies that we can actually apply in this non-muscle invasive setting for at this point, refractory disease. Can you maybe just give us a quick two-minute primer on that? Dr. Petros Grivas: Absolutely, and systemic therapies now come into play, as you said. And a classical example of that, Monty, came from the KEYNOTE-057 trial that we published about 6 years ago. This is intravenous pembrolizumab, given intravascularly, intravenously, as opposed to the previously discussed intravesical administration of agents. Pembrolizumab was tested in that KEYNOTE-057 trial and showed efficacy about, I would say, one out of five patients, about 20%, had a complete response of the tumor in the bladder in a year after starting the treatment. Again, it's hard to compare across different agents, but obviously when we give something intravenously, there is a risk of toxicity, side effects systemically, what we call immune-related adverse events. And this can also play in the decision making, right? When you have intravesical agents versus intravascular agents, there is different toxicity profiles in terms of systemic toxicity. But intravenous pembrolizumab has been an option, FDA approved, since, if I remember, it was early 2020 when this became FDA approved. There are other agents being tested in this disease, but like atezolizumab through the SWOG study that Dr. Black and Dr. Singh led, but atezolizumab is not FDA approved for this indication. Again, this is for BCG unresponsive, high-risk, non-muscle invasive bladder cancer. Dr. Sumanta (Monty) Pal: So maybe teach us how it works, for instance, at an expert center like the Fred Hutch. When you see a patient with non-muscle invasive bladder cancer, there's obviously the option of surgery, there's the intravesical therapies, which I imagine the urology team is still really at the helm of. But then, I guess there has to be consideration of all options. So you've got to bring up systemic therapy with agents like pembrolizumab. In that context, are you involved that early on in the conversation? Dr. Petros Grivas: That's a great discussion, Monty. Paradigm is shifting as we mentioned together. The urologists have been treating these patients and still they are the mainstay of the treaters, the managers in this disease. But medical oncologists come to play more and more, especially with the FDA approval of intravenous pembrolizumab about 5 years ago [GC1]  [KM2] . We have the concept of multidisciplinary bladder cancer clinic here at Fred Hutch and University of Washington. This happens every Tuesday morning, and we're very excited because it's a one-stop shop for the patients. We have the urologist, a medical oncologist, radiation oncologist, and experts from radiology and pathology, and we all review cases specifically with muscle-invasive bladder cancer. But every now and then, we see patients with BCG unresponsive non-muscle invasive bladder cancer. And this is where we discuss and we talk to the patient about pros and cons of all those options. And that's a classic example where medical oncologists may start to see those patients and offer their input and expertise. In addition to that, sometimes we have clinical trials, we may see these patients because there are systemic agents that may be administered in this setting. We have the SunRISe trial program that includes also a systemically administered checkpoint inhibitor. So that's another example where we see patients either in the context of multi-clinic or in individual solo clinics to counsel the patients about the pros and cons of the systemically administered agents in the context of clinical trials. Usually checkpoint inhibitors are the class of agents that are being tested in this particular scenario. Dr. Sumanta (Monty) Pal: I can see a scenario where it's really going to require this sort of deep dive, much in the way that we do for prostate cancer, for instance, where the medical oncologist is involved very early on and planning out any sort of systemic therapy component of treatment or at the very least, at least spelling out those options. I think it's going to be really interesting to see what this space looks like 5 or 10 years down the road. In closing, I wanted to go through something that I think is so different in this space, at least for the time being, and that is the paradigm for FDA approval. When you and I have our fellows in the clinics, we always say, “Look, you know, the paradigm in this disease and that disease and the other disease needs to be phase 3 randomized trials, right? Big thousand patient experiences where you're testing clinical endpoints.” That's tough in non-muscle invasive bladder cancer, right? Because thankfully, outcomes can actually be quite good, you know, in this setting, right? It's tough to actually estimate overall survival in some of these early-stage populations. Tell me what the current regulatory bar is, and this is a tough thing to do in 2 minutes or less but tell me where you see it headed. Dr. Petros Grivas: You alluded to that before, Monty, when I was giving the background and we talked about the regulatory approval. And I have to very quickly go back in time about 10 years ago because it's important for context that can help us in other disease types too. We had workshops with the FDA and the NCI with the help of the International Bladder Cancer Group and other colleagues. And we try to define a framework, what endpoints are meaningful for those patients in this disease. It was a multidisciplinary, multiple stakeholders meeting, where we tried to define what is important for patients. What are the available agents? What are the trial designs we can accept? And what are the meaningful endpoints that the regulatory agencies can accept for regulatory approval? And that was critical in that mission because it allowed us to design clinical trials, for example, single-arm trials in a disease where there was no standard of care. There was intravesical valrubicin and chemotherapy anthracycline that was approved for many years, but was not practically used in clinical practice, despite being approved, the valrubicin. And because of that, the FDA allowed these single-arm trials to happen. And obviously the endpoint was also discussed in that meeting. For example, for carcinoma in situ, complete response, clinical complete response, because the bladder remains intact in many patients, clinical complete response was a meaningful primary endpoint, also duration of response is also very important. So what is the durable clinical complete response in 1 year or 18 months is relevant. And when you have papillary tumors like Ta or T1 with CIS, for papillary tumors, event-free survival becomes one of the key endpoints and you look at it over time, for example, at 12 or 18 months, what is the event-free survival? So clinical complete response, duration of response, event-free survival, depending on the CIS presence or papillary tumors, I think these are endpoints that have allowed us to design those trials, get those agents approved.  Now, the question going forward, Monty, and we can close with that is, since now we have the embarrassment of riches, many more options available compared to where we were 6 and 7 years ago, is now the time to do randomized trials? And if we do randomized trials, which can be the control group? Which of those agents should be allowed to be part of the control group? These are ongoing discussions right now with the NCI, with other agencies, cooperative groups, trying to design those trials and move forward from here.[GC3]  Dr. Sumanta (Monty) Pal: Well, it's awesome to have you here on the program so we can get some early looks into some of these conversations. I mean, clearly, you're at the table at a lot of these discussions, Petros. So I want to thank you for sharing your insights with us today. This was just tremendous. Dr. Petros Grivas: Thank you, Monty. You know, patients in the center, I just came back from the Bladder Cancer Advocacy Network meeting in Washington, D.C., and we discussed all those questions, the topics you very eloquently mentioned and asked me today, and patients gave us great feedback and patients guide us in that effort. Thank you so, so much for having me and congratulations for the amazing podcast you're doing. Dr. Sumanta (Monty) Pal: Oh, cheers, Petros, thanks so much.  And thank you to the listeners who joined us today. If you really like the insights that you heard on this ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Thanks, everyone. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Find out more about today's speakers:      Dr. Sumanta (Monty) Pal  @montypal  Dr. Petros Grivas @PGrivasMDPhD   Follow ASCO on social media:     @ASCO on Twitter    ASCO on Bluesky   ASCO on Facebook     ASCO on LinkedIn     Disclosures:    Dr. Sumanta (Monty) Pal:   Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview  Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical  Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis  Dr. Petros Grivas: Consulting or Advisory Role: Merck, Bristol-Myers Squibb, AstraZeneca, EMD Serono, Pfizer, Janssen, Roche, Astellas Pharma, Gilead Sciences, Strata Oncology, Abbvie, Bicycle Therapeutics Replimune, Daiichi Sankyo, Foundation Medicine, Bicycle Therapeutics, Eli Lilly, Urogen Pharma, Tyra Biosciences Research Funding (Inst.): Bristol-Myers Squibb, Merck, EMD Serono, Gilead Sciences, Acrivon Therapeutics, ALX Oncology, ALX Oncology, Genentech Travel, Accommodations, Expenses: Gilead Sciences

The latest episode of Parsing Immigration Policy features Elizabeth Jacobs, Director of Regulatory Affairs and Policy at the Center for Immigration Studies, discussing USCIS's updated guidance on discretion in immigration benefits.Key Points:Beyond “Not a Criminal”: New USCIS policy updates require officers to engage in a more holistic analysis of whether naturalization applicants demonstrate “good moral character,” a requirement for naturalization that has been a part of U.S. immigration law since the beginning. In addition, the agency is now asking officers to consider any anti-American, antisemetic, or terrorist activity as “overwhelmingly negative” factors when evaluating whether an applicant warrants a positive grant of discretion.Discretionary Benefits: Many immigration benefits under the INA — including asylum, national interest waivers under EB-2, and naturalization — are discretionary. Even if eligibility requirements are met, USCIS officers may deny them.Good Moral Character Assessments:Traditionally treated as a checklist; now assessed holistically.Focuses on demonstrating positive attributes and rehabilitation, not just the absence of misconduct.Negative Factors for Discretionary Denials: Officers are instructed to treat support for anti-American ideologies, antisemitism, and terrorism as “overwhelmingly negative factors” when exercising discretion on discretionary immigration benefit requests.Expanded Use of Vetting Tools:Increased use of social media screening, fraud detection, and neighborhood/personal investigations.Previous policies often waived these investigations; the update clarifies they are a standard part of discretion.Balancing Efficiency and Vetting: With millions of applications annually, USCIS must balance rigorous vetting with timely processing. The agency is shifting culture to prioritize serving the American people, not just applicants.Cultural Shift: USCIS is shifting emphasis from serving as a “service agency” to serving as a vetting agency, using the discretion granted by Congress to protect national security and uphold American values — a departure from prior policies favoring mass approvals.Immigration Newsmaker Interview: USCIS Director Joe Edlow will be featured today in an Immigration Newsmaker conversation hosted by CIS at the National Press Club. The video will be available at cis.org.Host Mark Krikorian is the Executive Director of the Center for Immigration Studies.GuestElizabeth Jacobs is the Director of Regulatory Affairs and Policy at the Center for Immigration Studies.RelatedUSCIS to Consider Anti-Americanism, Antisemitism, and Terrorist Activity When Adjudicating Certain Immigration Benefit RequestsCIS National Security Vetting Failures DatabaseIntro MontageVoices in the opening montage:Sen. Barack Obama at a 2005 press conference.Sen. John McCain in a 2010 election ad.President Lyndon Johnson, upon signing the 1965 Immigration Act.Booker T. Washington, reading in 1908 from his 1895 Atlanta Exposition speech.Laraine Newman as a "Conehead" on SNL in 1977.Hillary Clinton in a 2003 radio interview.Cesar Chavez in a 1974 interview.House Speaker Nancy Pelosi speaking to reporters in 2019.Prof. George Borjas in a 2016 C-SPAN appearance.Sen. Jeff Sessions in 2008 comments on the Senate floor.Candidate Trump in 2015 campaign speech.Charlton Heston in "Planet of the Apes".

https://www.patreon.com/c/WereNotSorry https://revengeofthecis.locals.com/

In this episode, DB talks with Jamie Joy, a trans sex educator, to talk all things trans sex. Trans listeners, tune in for some fascinating conversations on things like hormones and finding what feels right for you. Cis listeners, there's tips for you too -- not just on how to give pleasure to your trans partner regardless of their anatomy, but how you might find more joy in yourself as well! This is a vital time to be tuning in to what our trans communities need, inside and outside of the bedroom. Guest DetailsJamie Joy (they/them) is a queer trans Jewish certified sex educator whose life and work is committed to spreading joy, consent, and pleasure through community organizing. They have been educating on a wide range of topics related to sex and sexuality for the past 10+ years with experience in K-12 schools, health clinics, college campuses, adult sex shops, national conferences, BDSM dungeons, non-profits, community organizations, and more. Jamie Joy loves to stay up late, throw an unforgettable party, and teach people about the wonders of fisting and fire play. They are always excited to connect and collaborate - find them on Instagram @thebadjewboy or their website www.jamiejoy.com Products Mentioned A blindfold Pleasure Feather Boundless Pleasure Wheel (pinwheel) The Magic Wand! (Try it over the clothes!) Silicone rings Sliquid Naturals Satin (menopause-friendly moisturizing lube) DB's FAVORITE lube -- SEXEDWITHDB for 10% off SpareParts Joque Harness Clone a Willy Kit Use SEXEDWITHDB for 15% off at Lion's Den! ABOUT SEASON 12 Season 12 of Sex Ed with DB is ALL ABOUT PLEASURE! Solo pleasure. Partnered pleasure. Orgasms. Porn. Queer joy. Kinks, sex toys, fantasies—you name it. We're here to help you feel more informed, more empowered, and a whole lot more turned on to help YOU have the best sex. CONNECT WITH US Instagram: @sexedwithdbpodcast TikTok: @sexedwithdbTwitter: @sexedwithdb Threads: @sexedwithdbpodcast YouTube: Sex Ed with DB SEX ED WITH DB SEASON 12 SPONSORS Lion's Den, Uberlube, & Magic Wand Get discounts on all of DB's favorite things here! GET IN TOUCH Email: sexedwithdb@gmail.comSubscribe to our BRAND NEW newsletter for hot goss, expert advice, and *the* most salacious stories. FOR SEXUAL HEALTH PROFESSIONALS Check out DB's workshop: "Building A Profitable Online Sexual Health Brand" ABOUT THE SHOW Sex Ed with DB is your go-to podcast for smart, science-backed sex education—delivering trusted insights from top experts on sex, sexuality, and pleasure. Empowering, inclusive, and grounded in real science, it's the sex ed you've always wanted. ASK AN ANONYMOUS SEX ED QUESTION Fill out our anonymous form to ask your sex ed question. SEASON 12 TEAM Creator, Host & Executive Producer: Danielle Bezalel (DB) (she/her) Communications Lead: Cathren Cohen (she/her) Growth Marketing Manager and Producer: Wil Williams (they/them) MUSIC Intro theme music: Hook Sounds Background music: Bright State by Ketsa Ad music: Soul Sync by Ketsa, Always Faithful by Ketsa, and Soul Epic by Ketsa. Thank you Ketsa!

Las bolas del bombo han decidido que esta madrugada repitamos el tema 'Tortilla', y que lo hagamos justo un día después de que el CIS haya publicado los resultados de su estudio 'Turismo y gastronomía III', en el que resuelven una de las grandes polémicas en torno a la tortilla: ¿cómo la prefieren los españoles? ¿con cebolla o sin cebolla? ¿poco o muy hecha? Lo comentamos con Silvia García, directora de investigación del CIS. También conocemos la historia de Abdo Al Alali, refugiado sirio, que a sus 22 años ha abierto un bar en el centro de Pamplona, la 'Cervecería Sirius'. Además ha compartido con nosotros la receta de la 'tortilla siria', el 'ejjeh'. Y el 'Gatopardo' de la noche ha sido el periodista Iñaki Gabilondo. 

Elena Sánchez asegura en sus 'Farolillos' que la tortilla debe estar jugosita, ni salada ni sosita y con bien de cebollita. Lo mismo que opina la mayoría de españoles, ya que según apunta una reciente encuesta realizada por el CIS, tres de cada cuatro españoles la prefieren con cebolla y el 53% poco hecha. Este "invento" extremeño es un manjar para cualquier paladar, ya seas de precocinados o un auténtico real foodie. No os perdáis las reacciones de los americanos probando la tortilla de patata por primera vez y las disparatadas sugerencias de mejora que plantean. 

This week, a major league baseball pitcher, who had a hard time staying on one team, or even in one league. His journeyman career took him all over the world, but his troubles started at home. He traded in one wife, for a new wife, costing himself millions of dollars. Opened a failed bar, that the "Bar Rescue" tv show couldn't save. But his real trouble started when he decided to shoot his in laws. A murder trial reveals an open marriage, an unlikely accomplice, and all kinds of crazy stuff!!   Try to embrace your Italian heritage, travel the world, being cut from different baseball teams, and murder your in laws, with the help of your wife's friend, who also happens to be your girlfriend with Dan "The Wolf" Serafini!!   Check us out, every Tuesday! We will continue to bring you the biggest idiots in sports history!!   Hosted by James Pietragallo & Jimmie Whisman   Donate at... patreon.com/crimeinsports or with paypal.com using our email: crimeinsports@gmail.com Get all the CIS, STM & YSO merch at crimeinsports.threadless.com   Go to shutupandgivememurder.com for all things CIS, STM & YSO!!   Contact us on... instagram.com/smalltownmurder facebook.com/crimeinsports crimeinsports@gmail.com

Rightwing media often spread the myth that trans people are violent or dangerous — a false narrative with zero evidence. These “trans terror” stories persist online and in the news, fueling real-world harm against the trans community. In this episode, Bridget and producer Joey Patt unpack the origins of these myths, explain why they stick, and show how the false idea of “trans terror” makes everyone less safe. A Trans Pilot Was Falsely Blamed for a Plane Crash. Now She’s Fighting the Right-Wing Disinfo Machine: https://www.wired.com/story/a-trans-pilot-was-falsely-blamed-for-a-plane-crash-now-shes-fighting-the-right-wing-disinfo-machine/ If you’re listening on Spotify, leave us a comment there! (Bridget personally reads them all!) or email us at hello@tangoti.com Follow Bridget and TANGOTI on social media || instagram.com/bridgetmarieindc || tiktok.com/@bridgetmarieindc || youtube.com/@ThereAreNoGirlsOnTheInternet See omnystudio.com/listener for privacy information. See omnystudio.com/listener for privacy information.

Episode 1541: Fat, Ratchet, & Thriving

https://morelikeradio.org/locals-ep-225-plus-sized-turf-war-preview/feed/ 0

Episode 1539: You Don’t Look Autistic    

A new episode of the Center for Immigration Studies podcast features Director of Litigation Julie Axelrod discussing the current status of the Center's landmark National Environmental Policy Act (NEPA) lawsuit, a new CIS case filed in Texas, and the recent “Alligator Alcatraz” litigation.Axelrod explains how the Trump administration is handling the remedy phase of Massachusetts Coalition for Immigration Reform v. Department of Homeland Security, where CIS successfully argued that the Biden administration violated NEPA when it dismantled border controls allowing in millions of people without doing any environmental impact analysis. NEPA, enacted in 1970, was intended to address environmental impacts of population growth – yet it has rarely been applied to immigration, despite its obvious relevance.Axelrod argues that applying NEPA consistently would protect the environment, provide transparency, and serve as an insurance policy to prevent future administrations from bypassing environmental review when expanding immigration.Highlights from the discussion with the Center's Executive Director Mark Krikorian include:CIS's Successful Lawsuit: The court found that the Biden administration had violated NEPA. The remedy phase could force DHS to conduct the environmental analysis that should have preceded both the Biden DHS's termination of the “Remain in Mexico” policy and halt in construction of the border wall, and/or could ensure that if a future administration repeats such actions, it would have to do environmental analysis, providing transparency and an opportunity for public input.Trump Administration on the Remedy: The Trump administration's immigration agenda, which largely focuses on reduction, not expansion, of immigration, would not be blocked if the administration were to embrace the idea that increases in immigration should be analyzed under NEPA prior to implementation. Such an embrace would also serve to make the Trump immigration agenda harder for a future administration to undo, as the Biden administration did to the first Trump administration's policies. Furthermore, as the Alligator Alcatraz case shows, whether the Trump administration embraces NEPA for immigration expansion or not, open-borders groups will continue challenging enforcement actions in court under NEPA.New Texas Lawsuit: A coalition of Texas plaintiffs seeks to apply NEPA to Biden-era policies, including the end of “Remain in Mexico,” expansive asylum rules, regulatory expansions to our work programs, and taxpayer-funded NGO programs.Alligator Alcatraz Case: Anti-enforcement groups are trying to use NEPA to block expansion of the Florida detention facility, highlighting a double standard – enforcement actions designed to reduce illegal immigration trigger environmental analysis, but policies that increase immigration do not (yet).Host Mark Krikorian is the Executive Director of the Center for Immigration Studies.GuestJulie Axelrod is the Director of Litigation at the Center for Immigration Studies.RelatedCIS Prevails in Challenge to Biden-Harris Immigration ActionsIntro MontageVoices in the opening montage:Sen. Barack Obama at a 2005 press conference.Sen. John McCain in a 2010 election ad.President Lyndon Johnson, upon signing the 1965 Immigration Act.Booker T. Washington, reading in 1908 from his 1895 Atlanta Exposition speech.Laraine Newman as a "Conehead" on SNL in 1977.Hillary Clinton in a 2003 radio interview.Cesar Chavez in a 1974 interview.House Speaker Nancy Pelosi speaking to reporters in 2019.Prof. George Borjas in a 2016 C-SPAN appearance.Sen. Jeff Sessions in 2008 comments on the Senate floor.Candidate Trump in 2015 campaign speech.Charlton Heston in "Planet of the Apes".

Send us a textWelcome to Season Six of Behind the Lines! The first episode of this season focuses on Houston people, service, and collaboration, in honor of HBA President Daniella Landers's goals for the new bar year. Listeners will hear from Houston lawyers (People) about legal trends in Houston's biggest industries, learn about how Houston lawyers can support those impacted by the Hill Country Flood (Service), find out how one Houston lawyer and his team helped clarify Texas family law in a pro bono case (Service), and explore two important ways lawyers in Houston are collaborating with those outside of the law to really make an impact (Collaboration). Part One: Houston ServiceHow to Help: Ways Houston Lawyers Can Support Those Impacted by the Hill Country Flood. Brittanny Gomez (Disaster Benefits Team Manager at Texas RioGrande Legal Aid), Jessie Campbell (Supervising Attorney for Private Attorney Involvement/Pro Bono at Lone Star Legal Aid), and Jillian Marullo (Pillsbury Winthrop Shaw Pittman), discuss ways attorneys in Houston can help those who were impacted by the Hill Country Flood. They talk about the legal issues presented by disasters like this, training and mentoring that is available, the importance of pro bono service, and vicarious trauma. (16 min.)Pro Bono Spotlight: Clarifying Texas Family Law and Making a Difference. Tony Lucisano (Baker Botts) discusses the legal issues presented and the Court's holding in a pro bono family law case he and his team took to the Texas Supreme Court. They secured a precedent-setting victory, which clarified evidentiary requirements for spousal maintenance awards in Texas. He also addresses the importance of pro bono service. (15 min.)Part Two: Houston People in Houston IndustriesEnergy Law Update. Jana Grauberger (co-leader of the Energy Practice Group at Liskow & Lewis) discusses issues impacting Houston energy lawyers, such as the impact of the One Big Beautiful Bill Act on oil and gas leasing in the Gulf and legal concerns related to the endangered Rice's whale. She also provides tips for young lawyers and students who are interested in the energy industry. (25 min.)Health Law Update. Megan Neel (DumasNeel) provides an update on what is happening in health care law in Houston, including the new non-compete law and updates to Texas law governing medical spas. She also provides tips for other lawyers and law students who are interested in this area of the law. (31 min.)Part Three: Houston CollaborationHVL's Medical Legal Partnerships: Collaborating to Care for the Whole Person. Susan Soto and Iris Onasis discuss Houston Volunteer Lawyers' Medical Legal Partnerships with Texas Children's Hospital and AccessHealth, including the types of legal issues they encounter, how Houston lawyers can volunteer to take cases, and how they support and mentor volunteer attorneys. (23 min.)Communities in Schools Houston: Collaborating for Confidence. Keiara Jones (partnership manager with Communities in Schools Houston (CIS)) describes how CIS, the HBA CIS Committee, and local legal employers collaborate to build confidence in local high school students by working together to provide them wiFor full speaker bios, visit The Houston Lawyer (hba.org/thehoustonlawyer). To read The Houston Lawyer magazine, visit The Houston Lawyer_home. For more information about the Houston Bar Association, visit Houston Bar Association (hba.org).*The views expressed in this episode do not necessarily reflect the views of The Houston Lawyer Editorial Board or the Houston Bar Association.

https://www.patreon.com/c/WereNotSorry https://revengeofthecis.locals.com/    

In episode 150 of Cybersecurity Where You Are, Sean Atkinson and Tony Sager are joined by Chad Rogers, Sr. Manager, Digital Media Services, at the Center for Internet Security® (CIS®); Rudy Uhde, Video Editor at CIS; and David Bisson, Sr. Content Strategist at CIS. Together, they use a roundtable chat to celebrate 150 episodes of Cybersecurity Where You Are. Here are some highlights from our episode:01:33. How the cybersecurity landscape and podcast have changed since Episode 10005:40. The "labor of love" that goes into editing and preparing an episode for publication12:13. Memorable guests and moments that changed the team's thinking about cybersecurity25:45. How the larger podcast team drives continuous improvement and innovation30:13. Parting thoughts for the audienceResourcesEpisode 100: Celebrating 100 Episodes and Looking AheadEpisode 149: Human Error, AI Missteps, and Other VM RisksEpisode 9: Mitigating Risk: Information Security GovernanceEpisode 96: Making Continuous Compliance Actionable for SMBsEpisode 121: The Economics of Cybersecurity Decision-MakingEpisode 114: 3 Board Chairs Reflect on 25 Years of CommunityEpisode 136: How WiCyS Advances Women in CybersecurityEpisode 120: How Contextual Awareness Drives AI GovernanceEpisode 116: AI-Enhanced Ransomware and Defending Against ItEpisode 146: What Security Looks Like for a Security CompanyEpisode 110: How Security Culture and Corporate Culture MeshIf you have some feedback or an idea for an upcoming episode of Cybersecurity Where You Are, let us know by emailing podcast@cisecurity.org.

This week, we tell the story of a man who never had much to call his own. Neglected, and abandoned at a young age, he grew up with no family. Luckily for him, he had basketball skills. Enough skills to make him only the 11th player to be drafted to the NBA, out of high school. Only problem is, he wasn't prepared for the league, or life. Next thing you know, he's covered in green war paint, and telling cops that he's "an Indian, fighting Columbus"!!   Be found wandering the streets at 5 years old, be drafted into the NBA, right out of high school, and don't take a break up with your high school sweetheart very well with Len"Fabulous Leon" Smith!!   Check us out, every Tuesday! We will continue to bring you the biggest idiots in sports history!!   Hosted by James Pietragallo & Jimmie Whisman   Donate at... patreon.com/crimeinsports or with paypal.com using our email: crimeinsports@gmail.com Get all the CIS, STM & YSO merch at crimeinsports.threadless.com   Go to shutupandgivememurder.com for all things CIS, STM & YSO!!   Contact us on... instagram.com/smalltownmurder facebook.com/crimeinsports crimeinsports@gmail.com

Episode 1538: Wrestling With Demons

pisode 1537: Nuts And Bolton

Episode 1536: Reservoir Dogs

https://www.patreon.com/c/WereNotSorry https://revengeofthecis.locals.com/  

This week, we check out a former Dallas Cowboy great, who started out by being given up by his mother, at age 2. He grew up in rough conditions, only to come out the other side as a star. Then, it all fell apart. Cocaine, booze, bad driving, fraud, fighting with girlfriends, and wandering the neighborhood, barefoot, banging on doors, and screaming for his wife. Also, several funny nicknames. Crazy story!   Find out you're adopted, when the DMV tells you so, be on the Dallas Cowboys, during the old time glory days, and get extremely into religion with John "Johnny Nightlife" Niland!!   Check us out, every Tuesday! We will continue to bring you the biggest idiots in sports history!!   Hosted by James Pietragallo & Jimmie Whisman   Donate at... patreon.com/crimeinsports or with paypal.com using our email: crimeinsports@gmail.com Get all the CIS, STM & YSO merch at crimeinsports.threadless.com   Go to shutupandgivememurder.com for all things CIS, STM & YSO!!   Contact us on... instagram.com/smalltownmurder facebook.com/crimeinsports crimeinsports@gmail.com

Episode 1535: A Relic Of The Past

Episode 1534: Saar Wars!

This week, we talk about an Olympic gold medalist boxer, who actually beat Mike Tyson, twice in one month! He came from South Central, LA, landing hinself in jail, at 13. His teen years bring more trouble, but a prison boxing program brings him to fame. Problem is, that fame is fleeting, and he keeps getrting arrested. For fraud, and even murder!   Start boxing in a prison program, take yourself all the way to an Olympic gold medal, and disgrace yourself with contant legal troubles, including a murder charge with Henry Tillman!!   Check us out, every Tuesday! We will continue to bring you the biggest idiots in sports history!!   Hosted by James Pietragallo & Jimmie Whisman   Donate at... patreon.com/crimeinsports or with paypal.com using our email: crimeinsports@gmail.com Get all the CIS, STM & YSO merch at crimeinsports.threadless.com   Go to shutupandgivememurder.com for all things CIS, STM & YSO!!   Contact us on... instagram.com/smalltownmurder facebook.com/crimeinsports crimeinsports@gmail.com

This week, we wrap up the story of one of the US's most notorious serial killers, with Randy, heading to more trials, even though he's already sentenced to over 100 years. All the while, Randy is in prison, writing all sorts of women, who send him money, and horrible photos. He also hooks up with a famous & deranged female murderer. Later, he is linked to many more killings. We may never know exactly how many he's killed!!   Keep writing women, and telling of your innocence, get engaged, several times, including to a notorious killer, and sue the person who wrote a book about you with Randall "The I-5 Killer" Woodfield - Part 7!!   Check us out, every Tuesday! We will continue to bring you the biggest idiots in sports history!!   Hosted by James Pietragallo & Jimmie Whisman   Donate at... patreon.com/crimeinsports or with paypal.com using our email: crimeinsports@gmail.com Get all the CIS, STM & YSO merch at crimeinsports.threadless.com   Go to shutupandgivememurder.com for all things CIS, STM & YSO!!   Contact us on... instagram.com/smalltownmurder facebook.com/crimeinsports crimeinsports@gmail.com